Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
The authors wish to make the following corrections to their article:
Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs in Context 2021; 10: 2021-2-6. DOI: 10.7573/dic.2021-2-6
